The Start-Up ElsaLys Biotech, a New Player in the Therapeutic Monoclonal Antibody Arena, Announces the First Round of Financing With TRANSGENE (TRGNY) and Sofimac Partners
5/17/2013 9:55:15 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
LYON, France & ILLKIRCH-GRAFFENSTADEN, France--(BUSINESS WIRE)--ElsaLys Biotech, which specializes in the development of therapeutic monoclonal antibodies, announces a first round of financing of 2.1M€ from the biopharmaceutical company Transgene and the investment fund Sofimac Partners.
Help employers find you! Check out all the jobs and post your resume.
comments powered by